Learn what vitamin B6 does in your body, including benefits for brain health, energy, immunity, heart health. Plus, the best food sources of this essential nutrient.

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

NEW findings presented at UK Kidney Week 2026 from the AIM CKD UK study suggest that commonly used creatinine-based equations to estimate glomerular filtration rate (eGFR) may substantially ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

Lower eGFR and higher urinary protein-to-creatinine ratio were associated with greater risks for cognitive impairment across the chronic kidney disease spectrum, according to study data published in ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 2:30 PM ESTCompany ParticipantsDave Gancarz - Chief Business ...